(Q53111672)

11 May 2018

title

Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. (English)

1 reference

11 May 2018

0 references

Riccardo Autorino

1 reference

11 May 2018

Francesco Cantiello

1 reference

11 May 2018

Antonio Cicione

1 reference

11 May 2018

Andrea Salonia

1 reference

11 May 2018

Luigi Tucci

1 reference

11 May 2018

Immacolata Madeo

1 reference

11 May 2018

Rocco Damiano

1 reference

11 May 2018

language of work or name

English

0 references

publication date

1 May 2013

1 reference

11 May 2018

published in

Urology

1 reference

11 May 2018

volume

1 reference

11 May 2018

issue

1 reference

11 May 2018

page(s)

1018-1023

1 reference

11 May 2018

Inflammation and chronic prostatic diseases: evidence for a link?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Asymptomatic inflammation and/or infection in benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Pancreatic fibrosis associated with age and ductal papillary hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Islet inflammation in type 2 diabetes: from metabolic stress to therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

The Abrams-Griffiths nomogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Comparison of urethral diameters for calculating the urethral dose after permanent prostate brachytherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Distribution of Inflammation, Pre-Malignant Lesions, Incidental Carcinoma in Histologically Confirmed Benign Prostatic Hyperplasia: A Retrospective Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Protective Association between Nonsteroidal Antiinflammatory Drug Use and Measures of Benign Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Anti-inflammatory drugs, antioxidants, and prostate cancer prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.01.053

10.1016/J.UROLOGY.2013.01.053

7 January 2021

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018